Samsung Biologics to invest $736m to build new drug manufacturing plant in South Korea
The facility, which will be built next to the company’s two existing plants, will have 180,000 liters of capacity. The company said in a filing that it expects
Teijin Pharma has signed a joint research agreement with Tokyo-based Aska Pharmaceutical to develop small-molecule drug candidates for gynaecological diseases.
Idarucizumab is indicated to reverse the anticoagulant effects of dabigatran etexilate during emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding. It binds specifically to